SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. ONON
6. AAPL
7. TRMD
8. AZN
9. NVDA
10. USO

Go back to SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) Delayed: 270.63 +0.41 (0.15%)
Previous Close $270.22    52 Week High $126.07 
Open $269.45    52 Week Low $94.28 
Day High $270.75    P/E 56.26 
Day Low $267.20    EPS $4.81 
Volume 3,200,705